Myriad Life Sciences and Woojeong Bio Join Hands to Expand the Bio Startup Ecosystem Base
Sung Sang-yong, CEO of Myriad Life Sciences (left), Cheon Byeong-nyeon, CEO of Woojeong Bio.
View original image[Asia Economy Reporter Lee Gwan-joo] Myriad Life Sciences, a strategic advisory and accelerator in the pharmaceutical and bio sector, announced on the 3rd that it has signed a memorandum of understanding (MOU) with Woojung Bio to expand the bio startup ecosystem.
Through this agreement, the two companies plan to establish a cooperative system to support research and development and technology commercialization consulting for bio startups. Specifically, they will collaborate on ▲building an open innovation support system for portfolio startups ▲integrated accelerating and related investment consulting ▲sharing global preclinical and clinical trial R&D strategies ▲discovering and incubating promising technology startups.
Myriad is a strategic advisory firm specializing in pharmaceuticals and bio, and officially launched a bio-specialized accelerator last month. It plans to initiate or discover promising startups in innovative new drug fields such as next-generation anticancer drugs and promote integrated accelerating and related investments. Currently, it supports three biotech companies: Abelos Therapeutics, Medici Bio, and Nio Biopharmaceuticals, and plans to expand its portfolio by initiating an antibody therapeutic startup within the first half of this year.
Woojung Bio is a bio infrastructure solution company pursuing a "one-stop new drug development ecosystem." Based on the Woojung Bio New Drug Cluster (hereinafter WooSinCl), completed last year, it provides preclinical research and consulting services. WooSinCl is Korea's first private-led, company-friendly new drug development cluster, equipped with comprehensive infrastructure for innovative new drug development, including the largest experimental animal research laboratory.
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051914165468840_1779167814.png)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "No Cure Available, Spread Accelerates... Already 105 Dead, American Infected"
- "If That's the Case, Why Not Just Buy Stocks?" ETFs in Name Only, Now 'Semiconductor-Heavy' and a Playground for Short-Term Traders
- "Reporters Who First Revealed Jo Jinwoong's Juvenile Offense History Cleared of Juvenile Act Violation"
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
Sung Sang-yong, CEO of Myriad Life Sciences, said, "Through this agreement, we expect the convergence of Myriad's differentiated advisory in new drug development and WooSinCl's cutting-edge new drug development infrastructure," adding, "It will be a support system contributing to the growth of many startups and pharmaceutical biotech companies."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
